Story
Melexis Stock Tumbles After Deutsche Bank Downgrade to 'Hold'

Summary
Shares of Belgian automotive chipmaker Melexis fell sharply after Deutsche Bank downgraded the stock to 'Hold' from 'Buy', citing broad sector headwinds despite an increased price target.
Shares of Melexis NV (MLXS), a Belgian automotive semiconductor specialist, fell more than 7% on Wednesday after Deutsche Bank downgraded its rating on the stock to 'Hold' from a previous 'Buy', prompting a wave of profit-taking.
The Analyst's Rationale
In a note to clients, Deutsche Bank analyst Robert Sanders cited a range of structural and cyclical headwinds across the technology hardware sector as the basis for the more cautious stance. The bank flagged several specific risks, including:
- Questions surrounding the monetization of artificial intelligence.
- Sluggish enterprise adoption of new technologies.
- The lingering effects of component shortage-driven double ordering.
- Potential pullbacks in capital expenditure from hyperscale data center operators.
Paradoxically, Deutsche Bank simultaneously raised its price target on Melexis to €75 from €65. However, the rating change proved more influential on investor sentiment for the day.
AdMarket Impact and Context
The downgrade followed a significant rally for the stock, which had surged approximately 39% over the past three months. With the shares opening Wednesday's session at €74.50 — already near the newly revised price target — investors appeared to see limited room for further near-term gains, triggering the sell-off.
The stock dropped to a session low of €71.80. Melexis's decline was an outlier in an otherwise positive market, with the S&P 500 and Nasdaq Composite posting solid gains. Key sector peers like STMicroelectronics and Infineon Technologies had no significant company-specific news, underscoring the Deutsche Bank report as the primary catalyst for Melexis's underperformance.
Investors will now look toward the company's next scheduled earnings release on July 29, 2026, for fresh fundamental data. While Wednesday's move pulls the stock back from its 52-week high of €86.70, it remains well above its 52-week low of €48.60.